HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

S Spazzapan Selected Research

Breast Neoplasms (Breast Cancer)

1/2018Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer.
9/2017Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
6/2015Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.
6/2012Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer.
2/2005Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors.
6/2003Treatment of older breast cancer patients with high recurrence risk.
1/2003Ifosfamide in advanced/disseminated breast cancer.
1/2001Fourteen-day infusion of ifosfamide in the management of advanced breast cancer refractory to protracted continuous infusion of 5-fluorouracil.
8/2000Combination chemotherapy with navelbine and continuous infusion of 5-fluorouracil in metastatic, chemotherapy refractory breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


S Spazzapan Research Topics

Disease

9Breast Neoplasms (Breast Cancer)
01/2018 - 08/2000
4Neoplasms (Cancer)
06/2015 - 01/2003
1Neutropenia
01/2018
1Asthenia
01/2018
1Amenorrhea
09/2017
1Disease Progression
06/2012
1Renal Cell Carcinoma (Grawitz Tumor)
08/2006
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
09/2005
1Infections
02/2005
1Febrile Neutropenia
02/2005
1Fatigue
10/2004

Drug/Important Bio-Agent (IBA)

2Alkylating AgentsIBA
01/2018 - 01/2003
2Hormones (Hormone)IBA
09/2017 - 06/2003
2IfosfamideFDA LinkGeneric
01/2003 - 01/2001
2Fluorouracil (Carac)FDA LinkGeneric
01/2001 - 08/2000
1vinflunineIBA
01/2018
1Triptorelin Pamoate (Trelstar)FDA Link
09/2017
1Gonadotropin-Releasing Hormone (GnRH)FDA Link
09/2017
1difluprednateFDA Link
06/2015
1SurvivinIBA
06/2015
1AntigensIBA
06/2015
1Mammaglobin AIBA
06/2015
1Capecitabine (Xeloda)FDA Link
06/2012
1Lapatinib (GW572016)FDA Link
06/2012
1ErbB Receptors (EGF Receptor)IBA
06/2012
1Trastuzumab (Herceptin)FDA Link
06/2012
1Interleukin-2 (IL2)IBA
08/2006
1Biomarkers (Surrogate Marker)IBA
08/2006
1Gefitinib (Iressa)FDA Link
09/2005
1Colony-Stimulating Factors (Colony Stimulating Factor)IBA
02/2005
1AnthracyclinesIBA
02/2005
1TamoxifenFDA LinkGeneric
06/2003
1Vinorelbine (Navelbine)FDA LinkGeneric
08/2000

Therapy/Procedure

5Drug Therapy (Chemotherapy)
01/2018 - 08/2000
2Adjuvant Chemotherapy
09/2017 - 06/2003
2Therapeutics
09/2017 - 06/2012
1Neoadjuvant Therapy
06/2015
1Retreatment
06/2012
1Catheters
01/2001
1Combination Drug Therapy (Combination Chemotherapy)
08/2000